Durability of Spike IgG Antibodies to SARS-CoV-2 Among Health Care Workers With Prior Infection | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Durability of Spike Immunoglobin G Antibodies to SARS-CoV-2 Among Health Care Workers With Prior Infection

Educational Objective
To identify the key insights or developments described in this article

Sign in to take quiz and track your certificates

Buy This Activity

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 27, 2021.

Published: August 30, 2021. doi:10.1001/jamanetworkopen.2021.23256

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Egbert ER et al. JAMA Network Open.

Corresponding Author: Amanda K. Debes, PhD, MS, Department of International Health, 615 N Wolfe St, E5036, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (adebes1@jhu.edu).

Author Contributions: Dr Milstone had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Egbert, Milstone, Debes.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Egbert, Colantuoni, Debes.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Xiao, Colantuoni, Debes.

Obtained funding: Milstone.

Administrative, technical, or material support: Egbert, Caturegli, Gadala, Debes.

Supervision: Milstone.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported through the generosity of the collective community of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for COVID research. Research reported in this publication was also supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number K24AI141580 (Dr Milstone).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional Contributions: The authors would like to thank members of the Johns Hopkins Hospital Clinical Immunology Laboratory, Danielle Koontz, MA, MS, and Annie Voskertchian, MPH, of the Johns Hopkins Division of Pediatric Infectious Diseases. Contributors received no additional compensation.

References
1.
Chen  X , Chen  Z , Azman  AS ,  et al.  Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.   Lancet Glob Health. 2021;9(5):e598-e609. doi:10.1016/S2214-109X(21)00026-7PubMedGoogle ScholarCrossref
2.
Rodda  LB , Netland  J , Shehata  L ,  et al.  Functional SARS-CoV-2–specific immune memory persists after mild COVID-19.   Cell. 2021;184(1):169-183.e17. doi:10.1016/j.cell.2020.11.029PubMedGoogle ScholarCrossref
3.
Caturegli  G , Materi  J , Howard  BM , Caturegli  P .  Clinical validity of serum antibodies to SARS-CoV-2 : a case-control study.   Ann Intern Med. 2020;173(8):614-622. doi:10.7326/M20-2889PubMedGoogle ScholarCrossref
4.
Manisty  C , Treibel  TA , Jensen  M ,  et al.  Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection.   EBioMedicine. 2021;65:103259. doi:10.1016/j.ebiom.2021.103259PubMedGoogle Scholar
5.
Van Elslande  J , Gruwier  L , Godderis  L , Vermeersch  P .  Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers.   Clin Infect Dis. 2021;ciab219. doi:10.1093/cid/ciab219PubMedGoogle Scholar
6.
Institute of Medicine.  Priorities for the National Vaccine Plan. National Academies Press; 2010.
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close